CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Mersana Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Mersana Therapeutics Inc
840 Memorial Drive
Phone: (617) 498-0020p:617 498-0020 CAMBRIDGE, MA  02139  United States Fax: (302) 636-5454f:302 636-5454
This company is no longer actively traded on any major stock exchange.
Business Summary
Mersana Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) and is engaged in developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company also focuses on adult oncology. Its pipeline includes tovorafenib (OJEMDA), DAY301, emiltatug ledadotin (Emi-Le), a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC). It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024YesYes-YesYes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board David M.Mott 59 1/1/2017 7/1/2012
President, Chief Executive Officer, Director Martin H.Huber 65 9/11/2023 4/13/2020
Chief Financial Officer, Chief Operating Officer, Senior Vice President BrianDeschuytner 47 9/5/2023 6/1/2019
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 102 (As of 12/31/2024)
Outstanding Shares: 4,998,750 (As of 11/10/2025)
Shareholders: 13
Stock Exchange: NASD
Federal Tax Id: 043562403
Fax Number: (302) 636-5454
Email Address: info@mersana.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, January 8, 2026